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Background: At present, the clinical breakpoints (CBPs) of both fluconazole and voricon-
azole are available only for 3 common Candida species in the Clinical and Laboratory 
Standards Institute (CLSI) and the European Committee on Antimicrobial Susceptibility 
Testing (EUCAST) methods. Epidemiological cutoff values (ECVs) were recently applied to 
both methods to detect the emergence of acquired resistance (i.e., non-wild-type isolates) 
among 5 common Candida species. 
Methods: We performed a nationwide study to determine the fluconazole and voriconazole 
susceptibility of Candida bloodstream isolates (BSIs) using both the CLSI and EUCAST 
methods. A total of 423 BSIs of 5 Candida species were collected from 8 hospitals. The 
azole susceptibilities were assessed on the basis of the species-specific CBPs and ECVs.
Results: Of the 341 BSIs of 3 common Candida species (i.e., C. albicans, C. tropicalis, 
and C. parapsilosis), 0.3% and 0.9%, 0.0% and 1.5% of isolates were categorized as flu-
conazole and voriconazole resistant according to the CLSI and EUCAST CBPs, respective-
ly. Of 423 total BSIs, 1.4% and 2.6% had fluconazole minimum inhibitory concentrations 
(MICs) exceeding the ECVs according to the CLSI and EUCAST, respectively; 1.0% and 
2.1% had voriconazole MICs exceeding the ECVs according to the CLSI and EUCAST, re-
spectively. Categorical agreement between the methods using ECVs was 98.3% for flucon-
azole and 98.3% for voriconazole. 
Conclusions: The EUCAST and CLSI methods using ECVs provide highly concordant re-
sults. Moreover, non-wild-type isolates with possibly acquired azole resistance were rare 
among the BSIs of 5 common Candida species in Korea.
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INTRODUCTION
Antifungal susceptibility testing against Candida is now recog-
nized as a useful aid in patient management and resistance 
surveillance [1-3]. There are 2 independent standards for anti-
fungal susceptibility testing against Candida: the broth microdi-
lution (BMD) method developed by the Clinical and Laboratory 
Standards Institute (CLSI) in the United States and the BMD 
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method of the European Committee on Antimicrobial Suscepti-
bility Testing (EUCAST) in Europe [4, 5]. These 2 methods are 
similar in that both use the BMD, while they differ in terms of in-
oculum size and minimum inhibitory concentration (MIC) end-
point determination [1]. Although both the CLSI and EUCAST 
have established clinical breakpoints (CBPs) for fluconazole and 
voriconazole, the EUCAST CBPs are species specific and apply 
only to Candida albicans, Candida tropicalis,  and Candida 
parapsilosis [1, 6, 7]. The CLSI is currently revising CBPs for dif-
ferent Candida species [1-3]. The originally proposed CLSI CBPs 
were not species specific, and assigned values for the suscepti-
bility to ≤8 μg/mL fluconazole and ≤1 μg/mL voriconazole were 
applied to all Candida species [4]. These CBPs are flawed in 
that a breakpoint is too high to provide a sensitive means of pre-
dicting the emergence of resistance among more susceptible 
species such as C. albicans, C. tropicalis, and C. parapsilosis 
and simultaneously bisects the wild-type distribution of Candida 
glabrata [1, 3]. Therefore, the CLSI subcommittee reconsidered 
the MIC distributions for each species and antifungal agent, and 
developed epidemiological cutoff values (ECVs); these ECV data 
were used in conjunction with molecular, pharmacodynamic, 
and clinical data to revise the CBPs to provide species-specific 
interpretative criteria [1-3]. ECVs may also be used to identify 
isolates that are less likely to respond to antimicrobial therapy 
because of acquired resistance mechanisms when limited clini-
cal data preclude the development of CBPs [3]. 
 The EUCAST first defined the wild-type (WT) MICs and ECVs 
for the 5 most common Candida species: C. albicans, C. tropi-
calis, C. parapsilosis, C. glabrata, and Candida krusei [1, 6, 7]. 
The WT MIC distribution is defined as the MIC distribution for 
isolates that exhibit no acquired or mutational resistance to the 
drug in question; meanwhile, non-WT isolates may possess ac-
quired or mutational resistance mechanisms [1, 6]. The upper 
limit of the WT population is defined as the ECV. ECVs have re-
cently been applied to EUCAST and CLSI antifungal susceptibil-
ity testing, and WT distributions from large collections of the 5 
most common Candida species show that the CLSI and EU-
CAST methods yield similar ECVs [1]. While CBPs are used to 
identify isolates likely to respond to treatment with a given anti-
microbial agent administered at its approved dosing regimen, 
the ECV may serve as the most sensitive measure of the emer-
gence of strains with reduced susceptibility (i.e., acquired resis-
tance) to that agent [3, 8, 9]. 
 To date, no data on the antifungal susceptibility of Candida 
bloodstream isolates (BSIs) have been obtained using the EU-
CAST method or species-specific CBPs or ECVs in Korea. 
Therefore, we performed a multicenter study to determine the 
susceptibilities of Candida BSIs to fluconazole and voriconazole 
in Korea using both the CLSI and EUCAST methods. We also 
applied the species-specific CBPs and ECVs for Candida BSIs, 
for the first time. In addition, we compared the CLSI and EU-
CAST BMD methods for testing 2 azole agents against Candida 
species using ECVs. 
METHODS
1. Candida isolates
All Candida BSIs were prospectively and routinely collected from 
blood cultures at 8 tertiary hospitals in Korea between Septem-
ber 2009 and August 2010. Some Candida isolates were provided 
by the Chonbuk National University Hospital Culture Collection 
for Pathogens. Duplicate C. albicans isolates from the same pa-
tient were excluded. Species identification and antifungal sus-
ceptibility testing of the Candida isolates were performed at 
Chonnam National University Hospital. Speciation was based on 
colony morphology on CHROMagar Candida (BBL, Becton Dick-
inson, Sparks, MD, USA) at 35˚C and a commercially available 
biochemical identification system (API 20C or Vitek 2 ID-YST; 
bioMérieux, Marcy L’Etoile, France). During the study period, a 
total of 440 Candida BSIs were collected from the 8 hospitals. Of 
these, 423 (96.1%) were the 5 most-common Candida species 
and were evaluated: 170 C. albicans, 93 C. tropicalis, 79 C. gla-
brata, 78 C. parapsilosis, and 3 C. krusei isolates). 
2. Antifungal susceptibility testing 
In vitro fluconazole and voriconazole susceptibility testing was 
performed on all isolates using both the CLSI and EUCAST 
BMD methods. The CLSI BMD method was performed accord-
ing to document M27-3 using RPMI 1640 medium containing 
0.165 M MOPS, an inoculum of 0.5-2.5×106 cells/L, and incu-
bation at 35°C [4]. In the CLSI method, the MICs were deter-
mined visually 24 hr after incubation as the lowest concentration 
of a drug that caused ≥50% inhibition in growth compared to 
control levels. The recently revised CLSI CBPs were used to 
identify Candida strains resistant to fluconazole and voricon-
azole. A fluconazole MIC ≤2 μg/mL was considered susceptible, 
4 μg/mL was considered susceptible dose dependent (SDD), 
and ≥8 μg/mL was considered resistant for C. albicans, C. 
parapsilosis, and C. tropicalis; a fluconazole MIC ≤32 μg/mL 
was considered SDD, while ≥64 μg/mL was considered resis-
tant for C. glabrata; a voriconazole MIC ≤0.12 μg/mL was con-
sidered susceptible, 0.25-0.5 μg/mL was considered intermedi-
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ate, and ≥1 μg/mL was considered resistant for C. albicans, C. 
parapsilosis, and C. tropicalis; a voriconazole MIC ≤0.5 μg/mL 
was considered susceptible, 1 μg/mL was considered intermedi-
ate, and ≥2 μg/mL was considered resistant for C. krusei [1-3].
 EUCAST BMD testing was performed as described in docu-
ment EDef 7.1 using RPMI 1640 medium containing 2.0% glu-
cose, an inoculum of 0.5-2.5×108 cells/L, and incubation at 
35°C [5]. MICs were determined as the lowest concentration of 
drug that resulted in ≥50% inhibition of growth compared to 
control levels spectrophotometrically at 530 nm after incubation 
for 24 hr. Interpretative breakpoints proposed by the EUCAST 
for fluconazole (susceptible, ≤2 μg/mL; resistant, >4 μg/mL) 
and voriconazole (susceptible, ≤0.125 μg/mL; resistant, >0.125 
μg/mL) were used for only C. albicans, C. parapsilosis, and C. 
tropicalis [6, 7]. Two reference strains, C. parapsilosis ATCC 
22019 and C. krusei ATCC 6258, were used as quality-control 
isolates in each antifungal susceptibility test. 
3. Comparison of the CLSI and EUCAST methods 
The fluconazole and voriconazole MIC results obtained by the 
EUCAST method were compared to those obtained by CLSI 
M27 BMD after incubation for 24 hr. Essential agreement was 
defined when the MICs from the 2 methods were within 2 dilu-
tions (i.e., 2 wells) of each other. Categorical agreement was ob-
tained on the basis of the recently described fluconazole and 
voriconazole ECVs for the CLSI-24 hr (0.5 and 0.03 μg/mL for C. 
albicans, 2 and 0.12 μg/mL for C. parapsilosis, 2 and 0.06 μg/
mL for C. tropicalis, 32 and 0.5 μg/mL for C. glabrata, and 64 
and 0.5 μg/mL for C. krusei, respectively) [1, 3] and EUCAST (1 
and 0.12 μg/mL for C. albicans, 2 and 0.12 μg/mL for C. parap-
silosis, 2 and 0.12 μg/mL C. tropicalis, 32 and 0.5 μg/mL for C. 
glabrata, and 128 and 1 μg/mL for C. krusei, respectively) [6, 7]. 
Isolates with MICs less than or equal to the respective ECVs 
were termed susceptible WT isolates, while the others were con-
sidered resistant non-WT isolates [1, 8, 9]. Discrepancies were 
considered to be very major when an isolate classified as non-
WT by the CLSI ECV was categorized as WT by the EUCAST 
ECV and major when an isolate classified as WT by the CLSI 
ECV was classified as non-WT by the EUCAST ECV.
RESULTS
Table 1 summarizes the in vitro susceptibilities of 423 BSIs of 5 
Candida species to fluconazole and voriconazole as determined 
by the CLSI and EUCAST BMD methods. For all 423 BSIs, the 
antifungal MIC ranges determined by the CLSI and EUCAST 
methods were similar: 0.125-64 µg/mL and 0.125-128 µg/mL for 
fluconazole and 0.03-2 µg/mL and 0.03-4 µg/mL for voricon-
azole, respectively. For most isolates, the fluconazole and vori-
conazole MICs obtained by the EUCAST method tended to be 
one twofold dilution higher than those obtained by the CLSI 
method. The overall rates of essential agreement (i.e., within 2 
dilutions) between the CLSI and EUCAST MIC results were 
97.6% for fluconazole and 98.3% for voriconazole. Of the 341 
BSIs of the 3 most common species (C. albicans, C. tropicalis, 
and C. parapsilosis), only 3 (0.9%) and 5 (1.5%) were resistant 
to fluconazole (MIC ≥8 μg/mL), and voriconazole (MIC ≥0.25 
μg/mL) according to the EUCAST method, respectively, and 1 
(0.3%) and 0 (0.0%) isolates were resistant to fluconazole (MIC 
≥8 μg/mL) and voriconazole (MIC ≥1 μg/mL) according to the 
CLSI method, respectively. Of the 79 C. glabrata isolates, only 3 
(3.8%) were fluconazole resistant (MIC ≥64 μg/mL), while the 
remaining 76 (96.2%) were SDD (MIC ≤32 μg/mL) according to 
the CLSI.    
 Table 2 shows categorical agreement between the results of 
the CLSI and EUCAST BMD methods for fluconazole and vori-
conazole using the ECVs. When the species-specific fluconazole 
ECVs were applied, the percentages of non-WT isolates deter-
mined by the CLSI and EUCAST methods were 0.6% and 0.0% 
for C. albicans, 0.0% and 2.2% for C. tropicalis, 3.8% and 5.1% 
for C. glabrata, 2.6% and 6.4% for C. parapsilosis, and 0.0% 
and 0.0% for C. krusei, respectively. In addition, the percent-
ages of non-WT isolates with voriconazole MICs exceeding the 
ECVs according to the CLSI and EUCAST BMD methods were 
0.0% and 0.0% for C. albicans, 0.0% and 4.3% for C. tropicalis, 
5.1% and 5.1% for C. glabrata, 0.0% and 1.4% for C. parapsilo-
sis, and 0.0% and 0.0% for C. krusei, respectively. Overall, when 
applying species-specific ECVs, 1.4% and 2.6% of isolates were 
categorized as fluconazole-resistant non-WT isolates (i.e., ex-
ceeding the ECVs) by the CLSI and EUCAST BMD methods, re-
spectively; meanwhile, 1.0% and 2.1% were categorized as vori-
conazole-resistant non-WT isolates, respectively. The percent-
ages of categorical agreement between the CLSI and EUCAST 
methods were 98.3% for fluconazole and 98.3% for voricon-
azole. The overall rates of categorical discrepancies between the 
EUCAST and CLSI methods were 1.6% for fluconazole (very 
major errors, 0.2%; major errors, 1.4%) and 1.7% for voricon-
azole (very major errors, 0.0%; major errors, 1.7%).   
DISCUSSION
The CLSI and EUCAST have both published ECVs for the 5 most 
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common Candida species against fluconazole and voriconazole; 
they are currently revising their species-specific CBPs for sev-
eral antifungal agents and various Candida species to further 
harmonize both methods [1-3]. Although revised species-spe-
cific CBPs for both fluconazole and voriconazole are not avail-
able for less common Candida species at present, the CLSI has 
proposed revised CBPs for 3 common Candida species by utiliz-
ing molecular, microbiologic, pharmacodynamic, and clinical 
data [3]. The EUCAST CBPs also apply only to 3 common Can-
dida species [6, 7]. When CBPs are unavailable, ECVs can be 
applied to local and global antifungal surveillance studies to de-
tect the emergence of antifungal resistance among Candida 
species [3, 8, 9]. The present study is the first to compare EU-
CAST and CLSI MIC results for BSIs of 5 common Candida spe-
cies from 8 hospitals in Korea and determine the fluconazole 
and voriconazole susceptibilities of Candida BSIs in Korea using 
species-specific CBPs and ECVs. 
 In the present study, only 1 (0.3%) isolate of 3 common Can-
dida species (i.e., C. albicans, C. tropicalis, and C. parapsilosis) 
was categorized as fluconazole resistant on the basis of the re-
vised CLSI CBPs; none were categorized as voriconazole resis-
tant. Meanwhile, only 3 (0.9%) and 5 (1.5%) isolates were resis-
tant to fluconazole and voriconazole, respectively, according to 
the EUCAST method. Several global surveillance programs us-
Table 1. In vitro antifungal susceptibilities of 423 bloodstream isolates of 5 common Candida species to fluconazole and voriconazole de-
termined by the CLSI and EUCAST methods
Species (N of 
isolates tested)
Antifungal 
agent
Test method*
MIC (μg/mL) Essential 
agreement (%)†
N (%) of isolates by category‡
Range Mode S SDD/I R 
C. albicans (170) Fluconazole CLSI 0.125-1 0.125 170 (100.0) 0 (0.0) 0 (0.0)
Fluconazole EUCAST 0.125-0.5 0.125 100.0 170 (100.0) NA 0 (0.0)
Voriconazole CLSI ≤0.03 0.03 170 (100.0) 0 (0.0) 0 (0.0)
Voriconazole EUCAST ≤0.03 0.03 100.0 170 (100.0) NA 0 (0.0)
C. tropicalis (93) Fluconazole CLSI 0.125-0.5 0.25 93 (100.0) 0 (0.0) 0 (0.0)
Fluconazole EUCAST 0.125-8 0.125 93.5 91 (97.8) NA 1 (1.1)
Voriconazole CLSI 0.03-0.06 0.03 93 (100.0) 0 (0.0) 0 (0.0)
Voriconazole EUCAST 0.03-4 0.03 95.7 89 (95.7) NA 4 (4.3)
C. glabrata (79) Fluconazole CLSI 1-64 4 NA 76 (96.2) 3 (3.8)
Fluconazole EUCAST 1-128 4 100.0 NA NA NA
Voriconazole CLSI 0.03-2 0.06 NA NA NA
Voriconazole EUCAST 0.03-4 0.125 97.5 NA NA NA
C. parapsilosis (78) Fluconazole CLSI 0.125-16 0.5 76 (97.4) 1 (1.4) 1 (1.4)
Fluconazole EUCAST 0.125-16 0.5 94.9 73 (93.6) NA 2 (2.6)
Voriconazole CLSI 0.03-0.125 0.03 78 (100.0) 0 (0.0) 0 (0.0)
Voriconazole EUCAST 0.03-0.5 0.03 98.7 77 (98.7) NA 1 (1.4)
C. krusei (3) Fluconazole CLSI 8-16 16 NA NA NA
Fluconazole EUCAST 16-32 32 100.0 NA NA NA
Voriconazole CLSI 0.06-0.125 0.06 3 (100.0) 0 (0.0) 0 (0.0)
Voriconazole EUCAST 0.06-0.25 0.125 100.0 NA NA NA
Total (423) Fluconazole CLSI 0.125-64 0.125
Fluconazole EUCAST 0.125-128 0.25 97.6
Voriconazole CLSI 0.03-2 0.03
Voriconazole EUCAST 0.015-4 0.015 98.3
*CLSI, MIC results obtained by CLSI M27-3 BMD method after 24-hr incubation; EUCAST, MIC results obtained by the BMD method of the EUCAST; †Es-
sential agreement (±2log (2) dilutions) between CLSI and EUCAST MICs; ‡The results were obtained by the recently revised CLSI CBPs [3] and CBPs pro-
posed by EUCAST [6, 7]
Abbreviations: CLSI, Clinical and Laboratory Standards Institute; EUCAST, European Committee on Antimicrobial Susceptibility Testing; S, susceptible; SDD, 
susceptible dose dependent; I, intermediate; R, resistant; NA, not available; BMD, broth microdilution; MIC, minimum inhibitory concentration; CBP, clinical 
breakpoint.
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ing CBPs also demonstrate that the majority of BSIs of 3 com-
mon Candida species are susceptible to fluconazole and vori-
conazole [10-13]. However, a recent study indicates a slight but 
consistent increase in possible resistance to fluconazole and 
voriconazole among non-WT isolates of 3 common Candida 
species according to the EUCAST and CLSI ECVs [8]. Although 
Candida isolates for which the azole MICs exceed the ECV may 
still respond to clinical treatment as the MIC may lie below the 
CBP, ECVs can be a sensitive measure for detecting the emer-
gence of Candida strains with decreased fluconazole and vori-
conazole susceptibility [1-3]. 
 To date, few comparative studies of CLSI and EUCAST anti-
fungal data obtained using ECVs have been performed, except 
one international study by Pfaller et al. [14]. This global multi-
center study determined the rates of non-WT isolates among 
1,056 clinical isolates of 5 common Candida species to be 3.0% 
and 5.5% for fluconazole and 2.6% and 4.3% for voriconazole 
on the basis of ECVs determined by the CLSI and EUCAST 
methods, respectively. In the present study, the prevalence of 
non-WT isolates was 1.4% and 2.6% using fluconazole ECVs 
determined by the CLSI and EUCAST BMD methods, respec-
tively, and 1.0% and 2.1% using voriconazole ECVs, respec-
Table 2. Categorical agreement between the results of the CLSI and EUCAST BMD methods for fluconazole and voriconazole and Candida 
species based on ECVs
Species (N of 
isolates tested)
Antifungal 
agent
Test method
ECV*
(µg/mL)
N of isolates (%) with 
indicated results: Categorical 
agreement (%)
% of categorical 
discrepancies†
≤ECV >ECV VM M
C. albicans (170) Fluconazole CLSI 0.5 169 (99.4) 1 (0.6)
Fluconazole EUCAST 1 170 (100.0) 0 (0.0)  99.4 0.6 0.0
Voriconazole CLSI 0.03 170 (100.0) 0 (0.0)
Voriconazole EUCAST 0.12 170 (100.0) 0 (0.0) 100.0 0.0 0.0
C. tropicalis (93) Fluconazole CLSI 2 93 (100.0) 0 (0.0)
Fluconazole EUCAST 2 91 (97.8) 2 (2.2)  97.8 0.0 2.2
Voriconazole CLSI 0.06 93 (100.0) 0 (0.0)
Voriconazole EUCAST 0.12 89 (95.7) 4 (4.3)  95.7 0.0 4.3
C. glabrata (79) Fluconazole CLSI 32 76 (96.2) 3 (3.8)
Fluconazole EUCAST 32 75 (94.9) 4 (5.1)  98.7 0.0 1.3
Voriconazole CLSI 0.5 75 (94.9) 4 (5.1)
Voriconazole EUCAST 1 75 (94.9) 4 (5.1)  97.5 0.0 2.5
C. parapsilosis (78) Fluconazole CLSI 2 76 (97.4) 2 (2.6)
Fluconazole EUCAST 2 73 (93.6) 5 (6.4)  96.2 0.0 3.8
Voriconazole CLSI 0.12 78 (100.0) 0 (0.0)
Voriconazole EUCAST 0.12 77 (98.7) 1 (1.4)  98.7 0.0 1.2
C. krusei (3) Fluconazole CLSI 64 3 (100.0) 0 (0.0)
Fluconazole EUCAST 128 3 (100.0) 0 (0.0) 100.0 0.0 0.0
Voriconazole CLSI 0.5 3 (100.0) 0 (0.0)
Voriconazole EUCAST 1 3 (100.0) 0 (0.0) 100.0 0.0 0.0
Total (423) Fluconazole CLSI 417 (98.6) 6 (1.4)
Fluconazole EUCAST 412 (97.4) 11 (2.6)  98.3 0.2 1.4
Voriconazole CLSI 419 (99.0) 4 (1.0)
Voriconazole EUCAST 414 (97.9) 9 (2.1)  98.3 0.0 1.7
*The ECVs of CLSI and EUCAST were obtained from references [1, 3, 6, 7]; †VM, very major discrepancies when an isolate classified as non-wild type (above 
ECV) by the CLSI ECV was categorized as wild type by the EUCAST ECV; M, major discrepancies when an isolate classified as wild type by the CLSI ECV was 
classified as non-wild type by the EUCAST ECV.
Abbreviations: CLSI, Clinical and Laboratory Standards Institute; EUCAST, European Committee on Antimicrobial Susceptibility Testing; BMD, broth microdi-
lution; ECV, epidemiological cutoff value.
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tively. These results show that the prevalence of non-WT BSIs of 
Candida species in Korea remains lower than that in other geo-
graphic regions. Pfaller et al. [15, 16] report that the prevalence 
of azole resistance among Candida isolates is variable both over 
time and by country and region. Although the prevalence of 
azole resistance among Candida species is not entirely related 
to antifungal drug pressure, our previous study provides the first 
evidence that increased fluconazole use can be significantly 
correlated with an increased number of fluconazole non-sus-
ceptible Candida isolates from clinical specimens [17]. 
 C. glabrata is innately less susceptible to azoles than most 
other Candida species and rapidly acquires secondary azole re-
sistance following exposure to fluconazole [18, 19]. The azole 
resistance frequency among C. glabrata BSIs may impact the 
empiric antifungal therapy choice [15]. The EUCAST has re-
frained from assigning CBPs for fluconazole and voriconazole to 
C. glabrata and advises alternative drugs to manage infections 
caused by this species [6, 7]. In contrast to the EUCAST, the 
CLSI recently revised the CBPs for fluconazole and C. glabrata 
to <32 μg/mL for SDD and ≥64 μg/mL for resistant with the ca-
veat that a maximum dose of fluconazole of 800 mg/day (12 mg/
kg/day) be used when treating C. glabrata infections with fluco-
nazole [3]. When the new CLSI CBPs were applied to the 79 C. 
glabrata isolates in the present study, 3 (3.8%) and 76 (96.2%) 
were resistant and SDD to fluconazole, respectively. In a previ-
ous global multicenter study, the prevalence of non-WT C. gla-
brata isolates according to the ECVs determined by the CLSI 
and EUCAST methods was 6.9% and 9.7% for fluconazole and 
9.1% and 15.4% for voriconazole, respectively [14]. In the pres-
ent study, the prevalence of non-WT C. glabrata isolates accord-
ing to the ECVs determined by the CLSI and EUCAST methods 
was 3.8% and 5.1% for fluconazole and 5.1% and 5.1% for vori-
conazole, respectively. These results show that the azole resis-
tance rates of C. glabrata BSIs in Korea remain lower than those 
in other geographic regions. 
 Similar to the present study, the global multicenter study by 
Pfaller et al. [14] demonstrates excellent essential agreement 
between the CLSI and EUCAST results with respect to suscepti-
bility to fluconazole (98.6% within 2 dilutions) and voriconazole 
(96.9%). Our data indicate excellent categorical agreement be-
tween the CLSI and EUCAST BMD methods for all 5 Candida 
species for both fluconazole (98.3%) and voriconazole (98.3%). 
Pfaller et al. [14] also observed excellent categorical agreement 
(96%) for all comparisons between the CLSI and EUCAST meth-
ods for all Candida species except C. parapsilosis (90.8% cate-
gorical agreement; 0.6% very major discrepancies). In their 
study, the prevalence of fluconazole resistance among C. parap-
silosis isolates was relatively high (17.9% and 9.9% determined 
by the EUCAST and CLSI methods, respectively). In the present 
study, the categorical agreement between the CLSI and EU-
CAST methods for C. parapsilosis was 96.2% and the preva-
lence of resistant non-WT C. parapsilosis isolates determined by 
the CLSI and EUCAST methods was 6.4% and 2.6%, respec-
tively. Therefore, the high categorical agreement in the present 
study may be due in part to the low frequency of fluconazole re-
sistance in our collection of BSIs of 5 Candida species common 
in Korea. 
 In conclusion, our data shows that the EUCAST and CLSI 
methods using ECVs provide highly concordant results for fluco-
nazole and voriconazole susceptibility in 5 Candida species. 
Furthermore, the results suggest ECVs are sensitive for detect-
ing the emergence of fluconazole and voriconazole resistance in 
these Candida species. When we examined the fluconazole and 
voriconazole susceptibilities of 5 major Candida BSIs using the 
ECVs, the rates of resistance were found to be low.
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